Emerging and novel functions of complement protein C1q

Frontiers in Immunology

Volumn 6, Issue JUN, 2015, Pages

  Kouser, Lubna ^a   Madhukaran, Shanmuga Priyaa ^a,b   Shastri, Abhishek ^c   Saraon, Anuvinder ^a   Ferluga, Janez ^a   Al Mozaini, Maha ^d   Kishore, Uday ^a  

^a BRUNEL UNIVERSITY   (United Kingdom)

^b Centre for Biotechnology and Bioinformatics Jawaharlal Nehru Institute for Advanced Studies School of Life Sciences   (India)

^c DORSET HEALTHCARE UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

^d KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

Author keywords

Apoptosis; C1q; Cancer; Complement; Neurogenesis; Pregnancy

Indexed keywords

ALPHA INTERFERON; AUTOANTIBODY; B LYMPHOCYTE RECEPTOR; CALRETICULIN; CD14 ANTIGEN; CD36 ANTIGEN; CD69 ANTIGEN; COLLECTIN; COMPLEMENT COMPONENT C1Q; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; DOUBLE STRANDED DNA; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HISTONE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOGLOBULIN G3; IMMUNOGLOBULIN M; INTERLEUKIN 10; INTERLEUKIN 12P70; INTERLEUKIN 6; INTERLEUKIN 7; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; PROSTAGLANDIN E2; STAT PROTEIN; STAT1 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 1; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG;

AGING; APOPTOSIS; AUTOIMMUNITY; B LYMPHOCYTE; CANCER CELL; CELL MATURATION; CENTRAL NERVOUS SYSTEM; COMPLEMENT SYSTEM; DENDRITIC CELL; FEMALE GENITAL SYSTEM; HUMAN; IMMUNOLOGICAL TOLERANCE; INFECTION; INFLAMMATION; MICROGLIA; MISSED ABORTION; NONHUMAN; PREECLAMPSIA; PREGNANCY; PRION DISEASE; PROTEIN AGGREGATION; PROTEIN EXPRESSION; REVIEW; SPONTANEOUS ABORTION; SYNAPSE; SYSTEMIC LUPUS ERYTHEMATOSUS; WOUND HEALING;

EID: 84935085624     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2015.00317     Document Type: Review

References (201)

1. Kishore U, Reid KB. Modular organization of proteins containing C1q-like globular domain. Immunopharmacology (1999) 42:15-21. doi:10.1016/S0162-3109(99)00011-9
2. Kishore U, Gupta SK, Perdikoulis MV, Kojouharova MS, Urban BC, Reid KB. Modular organization of the carboxyl-terminal, globular head region of human C1q A, B, and C chains. J Immunol (2003) 171:812-20. doi:10.4049/jimmunol.171.2.812
3. Sellar GC, Blake DJ, Reid KB. Characterization and organization of the genes encoding the A-, B- and C-chains of human complement subcomponent C1q. The complete derived amino acid sequence of human C1q. Biochem J (1991) 274(Pt 2):481-90.
4. Kishore U, Reid KB. C1q: structure, function, and receptors. Immunopharmacology (2000) 49:159-70. doi:10.1016/S0162-3109(00)80301-X
5. Reid KB, Porter RR. Subunit composition and structure of subcomponent C1q of the first component of human complement. Biochem J (1976) 155:19-23.
6. Gaboriaud C, Juanhuix J, Gruez A, Lacroix M, Darnault C, Pignol D, et al. The crystal structure of the globular head of complement protein C1q provides a basis for its versatile recognition properties. J Biol Chem (2003) 278:46974-82. doi:10.1074/jbc.M307764200
7. Kishore U, Gaboriaud C, Waters P, Shrive AK, Greenhough TJ, Reid KB, et al. C1q and tumor necrosis factor superfamily: modularity and versatility. Trends Immunol (2004) 25:551-61. doi:10.1016/j.it.2004.08.006
8. Shapiro L, Scherer PE. The crystal structure of a complement-1q family protein suggests an evolutionary link to tumor necrosis factor. Curr Biol (1998) 8:335-8. doi:10.1016/S0960-9822(98)70133-2
9. Kishore U, Ghai R, Greenhough TJ, Shrive AK, Bonifati DM, Gadjeva MG, et al. Structural and functional anatomy of the globular domain of complement protein C1q. Immunol Lett (2004) 95:113-28. doi:10.1016/j.imlet.2004.06.015
10. Castellano G, Trouw LA, Fiore N, Daha MR, Schena FP, van Kooten C. Infiltrating dendritic cells contribute to local synthesis of C1q in murine and human lupus nephritis. Mol Immunol (2010) 47:2129-37. doi:10.1016/j.molimm.2010.02.006
11. Foti M, Granucci F, Ricciardi-Castagnoli P. A central role for tissue-resident dendritic cells in innate responses. Trends Immunol (2004) 25:650-4. doi:10.1016/j.it.2004.10.007
12. van Kooten C, Fiore N, Trouw LA, Csomor E, Xu W, Castellano G, et al. Complement production and regulation by dendritic cells: molecular switches between tolerance and immunity. Mol Immunol (2008) 45:4064-72. doi:10.1016/j.molimm.2008.07.015
13. Zhou W, Peng Q, Li K, Sacks SH. Role of dendritic cell synthesis of complement in the allospecific T cell response. Mol Immunol (2007) 44:57-63. doi:10.1016/j.molimm.2006.06.012
14. Csomor E, Bajtay Z, Sandor N, Kristof K, Arlaud GJ, Thiel S, et al. Complement protein C1q induces maturation of human dendritic cells. Mol Immunol (2007) 44:3389-97. doi:10.1016/j.molimm.2007.02.014
15. Castellano G, Woltman AM, Nauta AJ, Roos A, Trouw LA, Seelen MA, et al. Maturation of dendritic cells abrogates C1q production in vivo and in vitro. Blood (2004) 103:3813-20. doi:10.1182/blood-2003-09-3046
16. Lood C, Gullstrand B, Truedsson L, Olin AI, Alm GV, Ronnblom L, et al. C1q inhibits immune complex-induced interferon-alpha production in plasmacytoid dendritic cells: a novel link between C1q deficiency and systemic lupus erythematosus pathogenesis. Arthritis Rheum (2009) 60:3081-90. doi:10.1002/art.24852
17. Meyaard L, Adema GJ, Chang C, Woollatt E, Sutherland GR, Lanier LL, et al. LAIR-1, a novel inhibitory receptor expressed on human mononuclear leukocytes. Immunity (1997) 7:283-90. doi:10.1016/S1074-7613(00)80530-0
18. Son M, Santiago-Schwarz F, Al-Abed Y, Diamond B. C1q limits dendritic cell differentiation and activation by engaging LAIR-1. Proc Natl Acad Sci U S A (2012) 109:E3160-7. doi:10.1073/pnas.1212753109
19. Cao W, Bobryshev YV, Lord RS, Oakley RE, Lee SH, Lu J. Dendritic cells in the arterial wall express C1q: potential significance in atherogenesis. Cardiovasc Res (2003) 60:175-86. doi:10.1016/S0008-6363(03)00345-6
20. Young KR Jr, Ambrus JL Jr, Malbran A, Fauci AS, Tenner AJ. Complement subcomponent C1q stimulates Ig production by human B lymphocytes. J Immunol (1991) 146:3356-64.
21. Ferry H, Potter PK, Crockford TL, Nijnik A, Ehrenstein MR, Walport MJ, et al. Increased positive selection of B1 cells and reduced B cell tolerance to intracellular antigens in C1q-deficient mice. J Immunol (2007) 178:2916-22. doi:10.4049/jimmunol.178.5.2916
22. Trendelenburg M, Manderson AP, Fossati-Jimack L, Walport MJ, Botto M. Monocytosis and accelerated activation of lymphocytes in C1q-deficient autoimmune-prone mice. Immunology (2004) 113:80-8. doi:10.1111/j.1365-2567.2004.01940.x
23. Fossati-Jimack L, Cortes-Hernandez J, Norsworthy PJ, Walport MJ, Cook HT, Botto M. C1q deficiency promotes the production of transgenic-derived IgM and IgG3 autoantibodies in anti-DNA knock-in transgenic mice. Mol Immunol (2008) 45:787-95. doi:10.1016/j.molimm.2007.06.162
24. Jacobson DL, Gange SJ, Rose NR, Graham NM. Epidemiology and estimated population burden of selected autoimmune diseases in the United States. Clin Immunol Immunopathol (1997) 84:223-43. doi:10.1006/clin.1997.4412
25. Ravichandran KS, Lorenz U. Engulfment of apoptotic cells: signals for a good meal. Nat Rev Immunol (2007) 7:964-74. doi:10.1038/nri2214
26. Slomp J, Gittenberger-de Groot AC, Glukhova MA, Conny van Munsteren J, Kockx MM, Schwartz SM, et al. Differentiation, dedifferentiation, and apoptosis of smooth muscle cells during the development of the human ductus arteriosus. Arterioscler Thromb Vasc Biol (1997) 17:1003-9. doi:10.1161/01.ATV.17.5.1003
27. Walport MJ, Davies KA, Botto M. C1q and systemic lupus erythematosus. Immunobiology (1998) 199:265-85. doi:10.1016/S0171-2985(98)80032-6
28. Goodnow CC, Sprent J, Fazekas de St Groth B, Vinuesa CG. Cellular and genetic mechanisms of self-tolerance and autoimmunity. Nature (2005) 435:590-7. doi:10.1038/nature03724
29. Carroll MC. The role of complement in B cell activation and tolerance. Adv Immunol (2000) 74:61-88. doi:10.1016/j.molimm.2004.03.017
30. Carroll MC. A protective role for innate immunity in systemic lupus erythematosus. Nat Rev Immunol (2004) 4:825-31. doi:10.1038/nri1456
31. Fadok VA, Bratton DL, Rose DM, Pearson A, Ezekewitz RA, Henson PM. A receptor for phosphatidylserine-specific clearance of apoptotic cells. Nature (2000) 405:85-90. doi:10.1038/35011084
32. Miyanishi M, Tada K, Koike M, Uchiyama Y, Kitamura T, Nagata S. Identification of Tim4 as a phosphatidylserine receptor. Nature (2007) 450:435-9. doi:10.1038/nature06307
33. Naito AT, Sumida T, Nomura S, Liu ML, Higo T, Nakagawa A, et al. Complement C1q activates canonical Wnt signaling and promotes aging-related phenotypes. Cell (2012) 149:1298-313. doi:10.1016/j.cell.2012.03.047
34. Agarwal V, Ahl J, Riesbeck K, Blom AM. An alternative role of C1q in bacterial infections: facilitating Streptococcus pneumoniae adherence and invasion of host cells. J Immunol (2013) 191:4235-45. doi:10.4049/jimmunol.1300279
35. Alberti S, Marques G, Hernandez-Alles S, Rubires X, Tomas JM, Vivanco F, et al. Interaction between complement subcomponent C1q and the Klebsiella pneumoniae porin OmpK36. Infect Immun (1996) 64:4719-25.
36. Roumenina LT, Popov KT, Bureeva SV, Kojouharova M, Gadjeva M, Rabheru S, et al. Interaction of the globular domain of human C1q with Salmonella typhimurium lipopolysaccharide. Biochim Biophys Acta (2008) 1784:1271-6. doi:10.1016/j.bbapap.2008.04.029
37. Agarwal V, Sroka M, Fulde M, Bergmann S, Riesbeck K, Blom AM. Binding of Streptococcus pneumoniae endopeptidase O (PepO) to complement component C1q modulates the complement attack and promotes host cell adherence. J Biol Chem (2014) 289:15833-44. doi:10.1074/jbc.M113.530212
38. Hong Q, Sze CI, Lin SR, Lee MH, He RY, Schultz L, et al. Complement C1q activates tumor suppressor WWOX to induce apoptosis in prostate cancer cells. PLoS One (2009) 4:e5755. doi:10.1371/journal.pone.0005755
39. Bossi F, Tripodo C, Rizzi L, Bulla R, Agostinis C, Guarnotta C, et al. C1q as a unique player in angiogenesis with therapeutic implication in wound healing. Proc Natl Acad Sci U S A (2014) 111:4209-14. doi:10.1073/pnas.1311968111
40. Korb LC, Ahearn JM. C1q binds directly and specifically to surface blebs of apoptotic human keratinocytes: complement deficiency and systemic lupus erythematosus revisited. J Immunol (1997) 158:4525-8.
41. Paidassi H, Tacnet-Delorme P, Garlatti V, Darnault C, Ghebrehiwet B, Gaboriaud C, et al. C1q binds phosphatidylserine and likely acts as a multiligand-bridging molecule in apoptotic cell recognition. J Immunol (2008) 180:2329-38. doi:10.4049/jimmunol.180.4.2329
42. Nayak A, Ferluga J, Tsolaki AG, Kishore U. The non-classical functions of the classical complement pathway recognition subcomponent C1q. Immunol Lett (2010) 131:139-50. doi:10.1016/j.imlet.2010.03.012
43. Ogden CA, deCathelineau A, Hoffmann PR, Bratton D, Ghebrehiwet B, Fadok VA, et al. C1q and mannose binding lectin engagement of cell surface calreticulin and CD91 initiates macropinocytosis and uptake of apoptotic cells. J Exp Med (2001) 194:781-95. doi:10.1084/jem.194.6.781
44. Martin M, Leffler J, Blom AM. Annexin A2 and A5 serve as new ligands for C1q on apoptotic cells. J Biol Chem (2012) 287:33733-44. doi:10.1074/jbc.M112.341339
45. Ghebrehiwet B, Lim BL, Kumar R, Feng X, Peerschke EI. gC1q-R/p33, a member of a new class of multifunctional and multicompartmental cellular proteins, is involved in inflammation and infection. Immunol Rev (2001) 180:65-77. doi:10.1034/j.1600-065X.2001.1800106.x
46. Ghebrehiwet B, Peerschke EI. Role of C1q and C1q receptors in the pathogenesis of systemic lupus erythematosus. Curr Dir Autoimmun (2004) 7:87-97. doi:10.1159/000075688
47. Stevens B, Allen NJ, Vazquez LE, Howell GR, Christopherson KS, Nouri N, et al. The classical complement cascade mediates CNS synapse elimination. Cell (2007) 131:1164-78. doi:10.1016/j.cell.2007.10.036
48. Pisalyaput K, Tenner AJ. Complement component C1q inhibits beta-amyloid- and serum amyloid P-induced neurotoxicity via caspase- and calpain-independent mechanisms. J Neurochem (2008) 104:696-707.
49. Klein MA, Kaeser PS, Schwarz P, Weyd H, Xenarios I, Zinkernagel RM, et al. Complement facilitates early prion pathogenesis. Nat Med (2001) 7:488-92. doi:10.1038/86567
50. Flores-Langarica A, Sebti Y, Mitchell DA, Sim RB, MacPherson GG. Scrapie pathogenesis: the role of complement C1q in scrapie agent uptake by conventional dendritic cells. J Immunol (2009) 182:1305-13. doi:10.4049/jimmunol.182.3.1305
51. Erlich P, Dumestre-Perard C, Ling WL, Lemaire-Vieille C, Schoehn G, Arlaud GJ, et al. Complement protein C1q forms a complex with cytotoxic prion protein oligomers. J Biol Chem (2010) 285:19267-76. doi:10.1074/jbc.M109.071860
52. Hosszu KK, Santiago-Schwarz F, Peerschke EI, Ghebrehiwet B. Evidence that a C1q/C1qR system regulates monocyte-derived dendritic cell differentiation at the interface of innate and acquired immunity. Innate Immun (2010) 16:115-27. doi:10.1177/1753425909339815
53. Lucas M, Stuart LM, Zhang A, Hodivala-Dilke K, Febbraio M, Silverstein R, et al. Requirements for apoptotic cell contact in regulation of macrophage responses. J Immunol (2006) 177:4047-54. doi:10.4049/jimmunol.177.6.4047
54. Chen A, Gaddipati S, Hong Y, Volkman DJ, Peerschke EI, Ghebrehiwet B. Human T cells express specific binding sites for C1q. Role in T cell activation and proliferation. J Immunol (1994) 153:1430-40.
55. Ghebrehiwet B, Habicht GS, Beck G. Interaction of C1q with its receptor on cultured cell lines induces an anti-proliferative response. Clin Immunol Immunopathol (1990) 54:148-60. doi:10.1016/0090-1229(90)90014-H
56. Botto M, Walport MJ. C1q, autoimmunity and apoptosis. Immunobiology (2002) 205:395-406. doi:10.1078/0171-2985-00141
57. Markiewski MM, Nilsson B, Ekdahl KN, Mollnes TE, Lambris JD. Complement and coagulation: strangers or partners in crime? Trends Immunol (2007) 28:184-92. doi:10.1016/j.it.2007.02.006
58. Botto M, Kirschfink M, Macor P, Pickering MC, Wurzner R, Tedesco F. Complement in human diseases: lessons from complement deficiencies. Mol Immunol (2009) 46:2774-83. doi:10.1016/j.molimm.2009.04.029
59. Steinman RM, Hawiger D, Liu K, Bonifaz L, Bonnyay D, Mahnke K, et al. Dendritic cell function in vivo during the steady state: a role in peripheral tolerance. Ann N Y Acad Sci (2003) 987:15-25. doi:10.1111/j.1749-6632.2003.tb06029.x
60. Carroll MC. The role of complement and complement receptors in induction and regulation of immunity. Annu Rev Immunol (1998) 16:545-68. doi:10.1146/annurev.immunol.16.1.545
61. Dempsey PW, Allison ME, Akkaraju S, Goodnow CC, Fearon DT. C3d of complement as a molecular adjuvant: bridging innate and acquired immunity. Science (1996) 271:348-50. doi:10.1126/science.271.5247.348
62. Malhotra R, Thiel S, Reid KB, Sim RB. Human leukocyte C1q receptor binds other soluble proteins with collagen domains. J Exp Med (1990) 172(3):955-9. doi:10.1084/jem.172.3.955
63. Ghebrehiwet B, Hosszu KK, Valentino A, Ji Y, Peerschke EI. Monocyte expressed macromolecular C1 and C1q receptors as molecular sensors of danger: implications in SLE. Front Immunol (2014) 5:278. doi:10.3389/fimmu.2014.00278
64. Ghebrehiwet B, Lim BL, Kumar R, Feng X, Peerschke EI. gC1q-R/p33, a member of a new class of multifunctional and multicompartmental cellular proteins, is involved in inflammation and infection. Immunol Rev (2001) 180:65-77. doi:10.1034/j.1600-065X.2001.1800106.x
65. Duus K, Hansen EW, Tacnet P, Frachet P, Arlaud GJ, Thielens NM, et al. Direct interaction between CD91 and C1q. FEBS J (2010) 277:3526-37. doi:10.1111/j.1742-4658.2010.07762.x
66. Hosszu KK, Valentino A, Vinayagasundaram U, Vinayagasundaram R, Joyce MG, Ji Y, et al. DC-SIGN, C1q, and gC1qR form a trimolecular receptor complex on the surface of monocyte-derived immature dendritic cells. Blood (2012) 120:1228-36. doi:10.1182/blood-2011-07-369728
67. Hoffmann PR, Kench JA, Vondracek A, Kruk E, Daleke DL, Jordan M, et al. Interaction between phosphatidylserine and the phosphatidylserine receptor inhibits immune responses in vivo. J Immunol (2005) 174:1393-404. doi:10.4049/jimmunol.174.3.1393
68. Idoyaga J, Fiorese C, Zbytnuik L, Lubkin A, Miller J, Malissen B, et al. Specialized role of migratory dendritic cells in peripheral tolerance induction. J Clin Invest (2013) 123:844-54. doi:10.1172/JCI65260
69. Jakubzick C, Gautier EL, Gibbings SL, Sojka DK, Schlitzer A, Johnson TE, et al. Minimal differentiation of classical monocytes as they survey steady-state tissues and transport antigen to lymph nodes. Immunity (2013) 39:599-610. doi:10.1016/j.immuni.2013.08.007
70. Navratil JS, Watkins SC, Wisnieski JJ, Ahearn JM. The globular heads of C1q specifically recognize surface blebs of apoptotic vascular endothelial cells. J Immunol (2001) 166:3231-9. doi:10.4049/jimmunol.166.5.3231
71. Nayak A, Pednekar L, Reid KB, Kishore U. Complement and non-complement activating functions of C1q: a prototypical innate immune molecule. Innate Immun (2012) 18:350-63. doi:10.1177/1753425910396252
72. Paidassi H, Tacnet-Delorme P, Verneret M, Gaboriaud C, Houen G, Duus K, et al. Investigations on the C1q-calreticulin-phosphatidylserine interactions yield new insights into apoptotic cell recognition. J Mol Biol (2011) 408:277-90. doi:10.1016/j.jmb.2011.02.029
73. Paidassi H, Tacnet-Delorme P, Lunardi T, Arlaud GJ, Thielens NM, Frachet P. The lectin-like activity of human C1q and its implication in DNA and apoptotic cell recognition. FEBS Lett (2008) 582:3111-6. doi:10.1016/j.febslet.2008.08.001
74. Hosszu KK, Valentino A, Ji Y, Matkovic M, Pednekar L, Rehage N, et al. Cell surface expression and function of the macromolecular c1 complex on the surface of human monocytes. Front Immunol (2012) 3:38. doi:10.3389/fimmu.2012.00038
75. Flannagan RS, Canton J, Furuya W, Glogauer M, Grinstein S. The phosphatidylserine receptor TIM4 utilizes integrins as coreceptors to effect phagocytosis. Mol Biol Cell (2014) 25:1511-22. doi:10.1091/mbc.E13-04-0212
76. Urban BC, Willcox N, Roberts DJ. A role for CD36 in the regulation of dendritic cell function. Proc Natl Acad Sci U S A (2001) 98:8750-5. doi:10.1073/pnas.151028698
77. Dai SY, Nakagawa R, Itoh A, Murakami H, Kashio Y, Abe H, et al. Galectin-9 induces maturation of human monocyte-derived dendritic cells. J Immunol (2005) 175:2974-81. doi:10.4049/jimmunol.175.5.2974
78. Anderson AC, Anderson DE, Bregoli L, Hastings WD, Kassam N, Lei C, et al. Promotion of tissue inflammation by the immune receptor Tim-3 expressed on innate immune cells. Science (2007) 318:1141-3. doi:10.1126/science.1148536
79. Monney L, Sabatos CA, Gaglia JL, Ryu A, Waldner H, Chernova T, et al. Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease. Nature (2002) 415:536-41. doi:10.1038/415536a
80. Ohyagi H, Onai N, Sato T, Yotsumoto S, Liu J, Akiba H, et al. Monocyte-derived dendritic cells perform hemophagocytosis to fine-tune excessive immune responses. Immunity (2013) 39:584-98. doi:10.1016/j.immuni.2013.06.019
81. Cortes JR, Sanchez-Diaz R, Bovolenta ER, Barreiro O, Lasarte S, Matesanz-Marin A, et al. Maintenance of immune tolerance by Foxp3+ regulatory T cells requires CD69 expression. J Autoimmun (2014) 55:51-62. doi:10.1016/j.jaut.2014.05.007
82. Valencia X, Yarboro C, Illei G, Lipsky PE. Deficient CD4+CD25high T regulatory cell function in patients with active systemic lupus erythematosus. J Immunol (2007) 178:2579-88. doi:10.4049/jimmunol.178.4.2579
83. Yao ZQ, Prayther D, Trabue C, Dong ZP, Moorman J. Differential regulation of SOCS-1 signalling in B and T lymphocytes by hepatitis C virus core protein. Immunology (2008) 125:197-207. doi:10.1111/j.1365-2567.2008.02829.x
84. Nakayama M, Akiba H, Takeda K, Kojima Y, Hashiguchi M, Azuma M, et al. Tim-3 mediates phagocytosis of apoptotic cells and cross-presentation. Blood (2009) 113:3821-30. doi:10.1182/blood-2008-10-185884
85. Zhang Y, Ma CJ, Wang JM, Ji XJ, Wu XY, Jia ZS, et al. Tim-3 negatively regulates IL-12 expression by monocytes in HCV infection. PLoS One (2011) 6:e19664. doi:10.1371/journal.pone.0019664
86. Chen M, Daha MR, Kallenberg CG. The complement system in systemic autoimmune disease. J Autoimmun (2010) 34:J276-86. doi:10.1016/j.jaut.2009.11.014
87. Manderson AP, Botto M, Walport MJ. The role of complement in the development of systemic lupus erythematosus. Annu Rev Immunol (2004) 22:431-56. doi:10.1146/annurev.immunol.22.012703.104549
88. Devitt A, Parker KG, Ogden CA, Oldreive C, Clay MF, Melville LA, et al. Persistence of apoptotic cells without autoimmune disease or inflammation in CD14-/- mice. J Cell Biol (2004) 167:1161-70. doi:10.1083/jcb.200410057
89. Stuart LM, Takahashi K, Shi L, Savill J, Ezekowitz RA. Mannose-binding lectin-deficient mice display defective apoptotic cell clearance but no autoimmune phenotype. J Immunol (2005) 174:3220-6. doi:10.4049/jimmunol.174.6.3220
90. Chatterjee P, Agyemang AF, Alimzhanov MB, Degn S, Tsiftsoglou SA, Alicot E, et al. Complement C4 maintains peripheral B-cell tolerance in a myeloid cell dependent manner. Eur J Immunol (2013) 43:2441-50. doi:10.1002/eji.201343412
91. Dal Ben ER, do Prado CH, Baptista TS, Bauer ME, Staub HL. Decreased levels of circulating CD4+CD25+Foxp3+ regulatory T cells in patients with primary antiphospholipid syndrome. J Clin Immunol (2013) 33:876-9. doi:10.1007/s10875-012-9857-y
92. Botto M, Dell'Agnola C, Bygrave AE, Thompson EM, Cook HT, Petry F, et al. Homozygous C1q deficiency causes glomerulonephritis associated with multiple apoptotic bodies. Nat Genet (1998) 19:56-9. doi:10.1038/ng0598-56
93. Fujimoto M, Sato S. B cell signaling and autoimmune diseases: CD19/CD22 loop as a B cell signaling device to regulate the balance of autoimmunity. J Dermatol Sci (2007) 46:1-9. doi:10.1016/j.jdermsci.2006.12.004
94. Grimaldi CM, Hicks R, Diamond B. B cell selection and susceptibility to autoimmunity. J Immunol (2005) 174:1775-81. doi:10.4049/jimmunol.174.4.1775
95. Carter RH, Fearon DT. CD19: lowering the threshold for antigen receptor stimulation of B lymphocytes. Science (1992) 256:105-7. doi:10.1126/science.1373518
96. Carroll MC. CD21/CD35 in B cell activation. Semin Immunol (1998) 10:279-86. doi:10.1006/smim.1998.0120
97. Cherukuri A, Cheng PC, Pierce SK. The role of the CD19/CD21 complex in B cell processing and presentation of complement-tagged antigens. J Immunol (2001) 167:163-72. doi:10.4049/jimmunol.167.1.163
98. Fujimoto M, Poe JC, Hasegawa M, Tedder TF. CD19 regulates intrinsic B lymphocyte signal transduction and activation through a novel mechanism of processive amplification. Immunol Res (2000) 22:281-98. doi:10.1385/IR:22:2-3:281
99. Kil LP, de Bruijn MJ, van Nimwegen M, Corneth OB, van Hamburg JP, Dingjan GM, et al. Btk levels set the threshold for B-cell activation and negative selection of autoreactive B cells in mice. Blood (2012) 119:3744-56. doi:10.1182/blood-2011-12-397919
100. Fujimoto M, Bradney AP, Poe JC, Steeber DA, Tedder TF. Modulation of B lymphocyte antigen receptor signal transduction by a CD19/CD22 regulatory loop. Immunity (1999) 11:191-200. doi:10.1016/S1074-7613(00)80094-1
101. Justement LB. The role of the protein tyrosine phosphatase CD45 in regulation of B lymphocyte activation. Int Rev Immunol (2001) 20:713-38. doi:10.3109/08830180109045587
102. Muller J, Nitschke L. The role of CD22 and Siglec-G in B-cell tolerance and autoimmune disease. Nat Rev Rheumatol (2014) 10:422-8. doi:10.1038/nrrheum.2014.54
103. Surolia I, Pirnie SP, Chellappa V, Taylor KN, Cariappa A, Moya J, et al. Functionally defective germline variants of sialic acid acetylesterase in autoimmunity. Nature (2010) 466:243-7. doi:10.1038/nature09115
104. Ding C, Ma Y, Chen X, Liu M, Cai Y, Hu X, et al. Integrin CD11b negatively regulates BCR signalling to maintain autoreactive B cell tolerance. Nat Commun (2013) 4:2813. doi:10.1038/ncomms3813
105. Shiow LR, Rosen DB, Brdickova N, Xu Y, An J, Lanier LL, et al. CD69 acts downstream of interferon-a/ß to inhibit S1P1 and lymphocyte egress from lymphoid organs. Nature (2006) 440:540-4. doi:10.1038/nature04606
106. Kim KB, Kim BW, Choo HJ, Kwon YC, Ahn BY, Choi JS, et al. Proteome analysis of adipocyte lipid rafts reveals that gC1qR plays essential roles in adipogenesis and insulin signal transduction. Proteomics (2009) 9:2373-82. doi:10.1002/pmic.200800811
107. Trendelenburg M. Antibodies against C1q in patients with systemic lupus erythematosus. Springer Semin Immunopathol (2005) 27:276-85. doi:10.1007/s00281-005-0007-y
108. Trouw LA, Groeneveld TW, Seelen MA, Duijs JM, Bajema IM, Prins FA, et al. Anti-C1q autoantibodies deposit in glomeruli but are only pathogenic in combination with glomerular C1q-containing immune complexes. J Clin Invest (2004) 114:679-88. doi:10.1172/JCI200421075
109. Dragon-Durey MA, Blanc C, Marinozzi MC, van Schaarenburg RA, Trouw LA. Autoantibodies against complement components and functional consequences. Mol Immunol (2013) 56:213-21. doi:10.1016/j.molimm.2013.05.009
110. Radanova M, Vasilev V, Deliyska B, Kishore U, Ikonomov V, Ivanova D. Anti-C1q autoantibodies specific against the globular domain of the C1qB-chain from patient with lupus nephritis inhibit C1q binding to IgG and CRP. Immunobiology (2012) 217:684-91. doi:10.1016/j.imbio.2011.11.007
111. Tsacheva I, Radanova M, Todorova N, Argirova T, Kishore U. Detection of autoantibodies against the globular domain of human C1q in the sera of systemic lupus erythematosus patients. Mol Immunol (2007) 44:2147-51. doi:10.1016/j.molimm.2006.09.009
112. Baines MG, Millar KG, Mills P. Studies of complement levels in normal human pregnancy. Obstet Gynecol (1974) 43:806-10.
113. Hopkinson ND, Powell RJ. Classical complement activation induced by pregnancy: implications for management of connective tissue diseases. J Clin Pathol (1992) 45:66-7. doi:10.1136/jcp.45.1.66
114. Richani K, Soto E, Romero R, Espinoza J, Chaiworapongsa T, Nien JK, et al. Normal pregnancy is characterized by systemic activation of the complement system. J Matern Fetal Neonatal Med (2005) 17:239-45. doi:10.1080/14767050500072722
115. Derzsy Z, Prohaszka Z, Rigo J Jr, Fust G, Molvarec A. Activation of the complement system in normal pregnancy and preeclampsia. Mol Immunol (2010) 47:1500-6. doi:10.1016/j.molimm.2010.01.021
116. Tedesco F, Narchi G, Radillo O, Meri S, Ferrone S, Betterle C. Susceptibility of human trophoblast to killing by human complement and the role of the complement regulatory proteins. J Immunol (1993) 151:1562-70.
117. Teisner B, Tornehave D, Hau J, Westergaard JG, Poulsen HK. The complement system in normal pregnancy. In: Chapman MG, Gedis Grudzinskas J, Chard T, editors. Implantation. London: Springer (1988). p. 177-82.
118. Bulla R, Agostinis C, Bossi F, Rizzi L, Debeus A, Tripodo C, et al. Decidual endothelial cells express surface-bound C1q as a molecular bridge between endovascular trophoblast and decidual endothelium. Mol Immunol (2008) 45:2629-40. doi:10.1016/j.molimm.2007.12.025
119. Faulk WP, Jarret R, Keane M, Johnson PM, Boackle RJ. Immunological studies of human placentae: complement components in immature and mature chorionic villi. Clin Exp Immunol (1980) 40(2):299-305.
120. Tedesco F, Radillo O, Candussi G, Nazzaro A, Mollnes TE, Pecorari D. Immunohistochemical detection of terminal complement complex and S protein in normal and pre-eclamptic placentae. Clin Exp Immunol (1990) 80:236-40. doi:10.1111/j.1365-2249.1990.tb05240.x
121. Weir PE. Immunofluorescent studies of the uteroplacental arteries in normal pregnancy. Br J Obstet Gynaecol (1981) 88(3):301-7. doi:10.1111/j.1471-0528.1981.tb00985.x
122. Holmes CH, Simpson KL. Complement and pregnancy: new insights into the immunobiology of the fetomaternal relationship. Baillieres Clin Obstet Gynaecol (1992) 6:439-60. doi:10.1016/S0950-3552(05)80005-7
123. Girardi G, Bulla R, Salmon JE, Tedesco F. The complement system in the pathophysiology of pregnancy. Mol Immunol (2006) 43:68-77. doi:10.1016/j.molimm.2005.06.017
124. Zhou Y, Genbacev O, Fisher SJ. The human placenta remodels the uterus by using a combination of molecules that govern vasculogenesis or leukocyte extravasation. Ann N Y Acad Sci (2003) 995:73-83. doi:10.1111/j.1749-6632.2003.tb03211.x
125. Davies M, Browne CM. Anti-trophoblast antibody responses during normal human pregnancy. J Reprod Immunol (1985) 7:285-97. doi:10.1016/0165-0378(85)90024-5
126. Rooney IA, Oglesby TJ, Atkinson JP. Complement in human reproduction: activation and control. Immunol Res (1993) 12:276-94. doi:10.1007/BF02918258
127. Imrie HJ, McGonigle TP, Liu DT, Jones DR. Reduction in erythrocyte complement receptor 1 (CR1, CD35) and decay accelerating factor (DAF, CD55) during normal pregnancy. J Reprod Immunol (1996) 31:221-7. doi:10.1016/0165-0378(96)00977-1
128. Holmes CH, Simpson KL, Wainwright SD, Tate CG, Houlihan JM, Sawyer IH, et al. Preferential expression of the complement regulatory protein decay accelerating factor at the fetomaternal interface during human pregnancy. J Immunol (1990) 144:3099-105.
129. Holmes CH, Simpson KL, Okada H, Okada N, Wainwright SD, Purcell DF, et al. Complement regulatory proteins at the feto-maternal interface during human placental development: distribution of CD59 by comparison with membrane cofactor protein (CD46) and decay accelerating factor (CD55). Eur J Immunol (1992) 22:1579-85. doi:10.1002/eji.1830220635
130. Abramson SB, Buyon JP. Activation of the complement pathway: comparison of normal pregnancy, preeclampsia, and systemic lupus erythematosus during pregnancy. Am J Reprod Immunol (1992) 28:183-7. doi:10.1111/j.1600-0897.1992.tb00787.x
131. Hsi BL, Hunt JS, Atkinson JP. Differential expression of complement regulatory proteins on subpopulations of human trophoblast cells. J Reprod Immunol (1991) 19:209-23. doi:10.1016/0165-0378(91)90036-P
132. Miyano A, Nakayama M, Fujita T, Kitajima H, Imai S, Shimizu A. Complement activation in fetuses: assessment by the levels of complement components and split products in cord blood. Diagn Clin Immunol (1987) 5:86-90.
133. Sonntag J, Brandenburg U, Polzehl D, Strauss E, Vogel M, Dudenhausen JW, et al. Complement system in healthy term newborns: reference values in umbilical cord blood. Pediatr Dev Pathol (1998) 1(2):131-5. doi:10.1007/s100249900016
134. Stabile I, Nicolaides KH, Bach A, Teisner B, Rodeck C, Westergaard JG, et al. Complement factors in fetal and maternal blood and amniotic fluid during the second trimester of normal pregnancy. Br J Obstet Gynaecol (1988) 95:281-5. doi:10.1111/j.1471-0528.1988.tb06870.x
135. Wells M, Bennett J, Bulmer JN, Jackson P, Holgate CS. Complement component deposition in uteroplacental (spiral) arteries in normal human pregnancy. J Reprod Immunol (1987) 12:125-35. doi:10.1016/0165-0378(87)90040-4
136. Goldberg M, Luknar-Gabor N, Keidar R, Katz Y. Synthesis of complement proteins in the human chorion is differentially regulated by cytokines. Mol Immunol (2007) 44:1737-42. doi:10.1016/j.molimm.2006.07.298
137. Agostinis C, Bulla R, Tripodo C, Gismondi A, Stabile H, Bossi F, et al. An alternative role of C1q in cell migration and tissue remodeling: contribution to trophoblast invasion and placental development. J Immunol (2010) 185:4420-9. doi:10.4049/jimmunol.0903215
138. Madhukaran SP, Kishore U, Jamil K, Choolani M, Lu J. Decidual expression and localization of human surfactant protein SP-A and SP-D, and complement protein C1q. Mol Immunol (2015) 66(2):197-207. doi:10.1016/j.molimm.2015.03.001
139. Singh J, Ahmed A, Girardi G. Role of complement component C1q in the onset of preeclampsia in mice. Hypertension (2011) 58(4):716-24. doi:10.1161/HYPERTENSIONAHA.111.175919
140. Agostinis C, Bossi F, Masat E, Radillo O, Tonon M, De Seta F, et al. MBL interferes with endovascular trophoblast invasion in pre-eclampsia. Clin Dev Immunol (2012) 2012:484321. doi:10.1155/2012/484321
141. Hoogenkamp M, Krysinska H, Ingram R, Huang G, Barlow R, Clarke D, et al. The Pu.1 locus is differentially regulated at the level of chromatin structure and noncoding transcription by alternate mechanisms at distinct developmental stages of hematopoiesis. Mol Cell Biol (2007) 27:7425-38. doi:10.1128/MCB.00905-07
142. Madhukaran SP, Kishore U, Jamil K, Teo BHD, Choolani M, Lu J. Transcriptional factor PU.1 regulates decidual C1q expression in early pregnancy in human. Front Immunol (2015) 6:53. doi:10.3389/fimmu.2015.00053
143. Lokki AI, Heikkinen-Eloranta J, Jarva H, Saisto T, Lokki ML, Laivuori H, et al. Complement activation and regulation in preeclamptic placenta. Front Immunol (2014) 5:312. doi:10.3389/fimmu.2014.00312
144. Daponte A, Deligeoroglou E, Pournaras S, Hadjichristodoulou C, Garas A, Anastasiadou F, et al. Interleukin-15 (IL-15) and anti-C1q antibodies as serum biomarkers for ectopic pregnancy and missed abortion. Clin Dev Immunol (2013) 2013:637513. doi:10.1155/2013/637513
145. Storelli MM, Barone G, Storelli A, Marcotrigiano GO. Levels and congener profiles of PCBs and PCDD/Fs in blue shark (Prionace glauca) liver from the South-Eastern Mediterranean Sea (Italy). Chemosphere (2011) 82:37-42. doi:10.1016/j.chemosphere.2010.10.014
146. Gu P, Gao LJ, Li L, Liu Z, Luan FQ, Peng YZ, et al. Endocrine disruptors, polychlorinated biphenyls-induced gC1qR-dependent apoptosis in human trophoblast cell line HTR-8/SVneo. Reprod Sci (2012) 19(2):181-9. doi:10.1177/1933719111415866
147. Tamblyn JA, Lissauer DM, Powell R, Cox P, Kilby MD. The immunological basis of villitis of unknown etiology - review. Placenta (2013) 34:846-55. doi:10.1016/j.placenta.2013.07.002
148. Altemani AM, Norato D, Baumel C. Immunological studies in placentas with villitis of unknown etiology: complement components and immunoglobulins in chorionic villi. J Perinat Med (1992) 20:129-34. doi:10.1515/jpme.1992.20.2.129
149. Benirschke K, Kaufmann P, Baergen RN. Pathology of the Human placenta. New York, NY: Springer Science and Bussiness Media (2006).
150. Chagas C. Nova tripanozomiaze humana: estudos sobre a morfolojia e o ciclo evolutivo do Schizotrypanum cruzi n. gen., n. sp., ajente etiolojico de nova entidade morbida do homem. Mem Inst Oswaldo Cruz (1909) 1:159-218. doi:10.1590/S0074-02761909000200008
151. Shippey SH III, Zahn CM, Cisar MM, Wu TJ, Satin AJ. Use of the placental perfusion model to evaluate transplacental passage of Trypanosoma cruzi. Am J Obstet Gynecol (2005) 192:586-91. doi:10.1016/j.ajog.2004.07.079
152. Ramos R, Juri M, Ramos A, Hoecker G, Lavandero S, Pena P, et al. An immunogenetically defined and immunodominant Trypanosoma cruzi antigen. Am J Trop Med Hyg (1991) 44:314-22.
153. Ferreira V, Valck C, Sanchez G, Gingras A, Tzima S, Molina MC, et al. The classical activation pathway of the human complement system is specifically inhibited by calreticulin from Trypanosoma cruzi. J Immunol (2004) 172:3042-50. doi:10.4049/jimmunol.172.5.3042
154. Molina MC, Ferreira V, Valck C, Aguilar L, Orellana J, Rojas A, et al. An in vivo role for Trypanosoma cruzi calreticulin in antiangiogenesis. Mol Biochem Parasitol (2005) 140:133-40. doi:10.1016/j.molbiopara.2004.12.014
155. Castillo C, Ramirez G, Valck C, Aguilar L, Maldonado I, Rosas C, et al. The interaction of classical complement component C1 with parasite and host calreticulin mediates Trypanosoma cruzi infection of human placenta. PLoS Negl Trop Dis (2013) 7:e2376. doi:10.1371/journal.pntd.0002376
156. Nowicki S, Martens MG, Nowicki BJ. Gonococcal infection in a nonhuman host is determined by human complement C1q. Infect Immun (1995) 63:4790-4.
157. Masat E, Bossi F, Agostinis C, Tonon M, Radillo O, De Seta F, et al. C1q is responsible of the anti-inflammatory behavior of decidual endothelial cells. J Reprod Immunol (2012) 94(1):91. doi:10.1016/j.jri.2012.03.409
158. Franklin RD, Kutteh WH. Effects of unfractionated and low molecular weight heparin on anti-phospholipid antibody binding in vitro. Obstet Gynecol (2003) 101:455-62. doi:10.1016/S0029-7844(02)02520-6
159. Girardi G, Redecha P, Salmon JE. Heparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation. Nat Med (2004) 10:1222-6. doi:10.1038/nm1121
160. Hills FA, Abrahams VM, Gonzalez-Timon B, Francis J, Cloke B, Hinkson L, et al. Heparin prevents programmed cell death in human trophoblast. Mol Hum Reprod (2006) 12:237-43. doi:10.1093/molehr/gal026
161. Bose P, Black S, Kadyrov M, Bartz C, Shlebak A, Regan L, et al. Adverse effects of lupus anticoagulant positive blood sera on placental viability can be prevented by heparin in vitro. Am J Obstet Gynecol (2004) 191:2125-31. doi:10.1016/j.ajog.2004.05.014
162. Ganapathy R, Whitley GS, Cartwright JE, Dash PR, Thilaganathan B. Effect of heparin and fractionated heparin on trophoblast invasion. Hum Reprod (2007) 22:2523-7. doi:10.1093/humrep/dem201
163. Almeda S, Rosenberg RD, Bing DH. The binding properties of human complement component C1q; interaction with mucopolysaccharides. J Biol Chem (1983) 258:785-91.
164. Oberkersch R, Attorresi AI, Calabrese GC. Low-molecular-weight heparin inhibition in classical complement activation pathway during pregnancy. Thromb Res (2010) 125:e240-5. doi:10.1016/j.thromres.2009.11.030
165. Shastri A, Bonifati DM, Kishore U. Innate immunity and neuroinflammation. Mediators Inflamm (2013) 2013:342931. doi:10.1155/2013/342931
166. Veerhuis R, Nielsen HM, Tenner AJ. Complement in the brain. Mol Immunol (2011) 48:1592-603. doi:10.1016/j.molimm.2011.04.003
167. Woodruff TM, Ager RR, Tenner AJ, Noakes PG, Taylor SM. The role of the complement system and the activation fragment C5a in the central nervous system. Neuromolecular Med (2010) 12:179-92. doi:10.1007/s12017-009-8085-y
168. Webster SD, Yang AJ, Margol L, Garzon-Rodriguez W, Glabe CG, Tenner AJ. Complement component C1q modulates the phagocytosis of Abeta by microglia. Exp Neurol (2000) 161:127-38. doi:10.1006/exnr.1999.7260
169. Fonseca MI, Zhou J, Botto M, Tenner AJ. Absence of C1q leads to less neuropathology in transgenic mouse models of Alzheimer's disease. J Neurosci (2004) 24:6457-65. doi:10.1523/JNEUROSCI.0901-04.2004
170. Fonseca MI, Kawas CH, Troncoso JC, Tenner AJ. Neuronal localization of C1q in preclinical Alzheimer's disease. Neurobiol Dis (2004) 15:40-6. doi:10.1016/j.nbd.2003.09.004
171. Luo X, Weber GA, Zheng J, Gendelman HE, Ikezu T. C1q-calreticulin induced oxidative neurotoxicity: relevance for the neuropathogenesis of Alzheimer's disease. J Neuroimmunol (2003) 135:62-71. doi:10.1016/S0165-5728(02)00444-7
172. Depboylu C, Schafer MK, Arias-Carrion O, Oertel WH, Weihe E, Hoglinger GU. Possible involvement of complement factor C1q in the clearance of extracellular neuromelanin from the substantia nigra in Parkinson disease. J Neuropathol Exp Neurol (2011) 70:125-32. doi:10.1097/NEN.0b013e31820805b9
173. Ingram G, Loveless S, Howell OW, Hakobyan S, Dancey B, Harris CL, et al. Complement activation in multiple sclerosis plaques: an immunohistochemical analysis. Acta Neuropathol Commun (2014) 2:53. doi:10.1186/2051-5960-2-53
174. Hakobyan S, Boyajyan A, Sim RB. Classical pathway complement activity in schizophrenia. Neurosci Lett (2005) 374:35-7. doi:10.1016/j.neulet.2004.10.024
175. Galvan MD, Luchetti S, Burgos AM, Nguyen HX, Hooshmand MJ, Hamers FP, et al. Deficiency in complement C1q improves histological and functional locomotor outcome after spinal cord injury. J Neurosci (2008) 28:13876-88. doi:10.1523/JNEUROSCI.2823-08.2008
176. Pedersen ED, Loberg EM, Vege E, Daha MR, Maehlen J, Mollnes TE. In situ deposition of complement in human acute brain ischaemia. Scand J Immunol (2009) 69:555-62. doi:10.1111/j.1365-3083.2009.02253.x
177. Ten VS, Sosunov SA, Mazer SP, Stark RI, Caspersen C, Sughrue ME, et al. C1q-deficiency is neuroprotective against hypoxic-ischemic brain injury in neonatal mice. Stroke (2005) 36:2244-50. doi:10.1161/01.STR.0000182237.20807.d0
178. Singhrao SK, Neal JW, Morgan BP, Gasque P. Increased complement biosynthesis by microglia and complement activation on neurons in Huntington's disease. Exp Neurol (1999) 159:362-76. doi:10.1006/exnr.1999.7170
179. Lynch NJ, Willis CL, Nolan CC, Roscher S, Fowler MJ, Weihe E, et al. Microglial activation and increased synthesis of complement component C1q precedes blood-brain barrier dysfunction in rats. Mol Immunol (2004) 40:709-16. doi:10.1016/j.molimm.2003.08.009
180. Farber K, Cheung G, Mitchell D, Wallis R, Weihe E, Schwaeble W, et al. C1q, the recognition subcomponent of the classical pathway of complement, drives microglial activation. J Neurosci Res (2009) 87:644-52. doi:10.1002/jnr.21875
181. Fraser DA, Pisalyaput K, Tenner AJ. C1q enhances microglial clearance of apoptotic neurons and neuronal blebs, and modulates subsequent inflammatory cytokine production. J Neurochem (2010) 112:733-43. doi:10.1111/j.1471-4159.2009.06494.x
182. Rambach G, Maier H, Vago G, Mohsenipour I, Lass-Florl C, Defant A, et al. Complement induction and complement evasion in patients with cerebral aspergillosis. Microbes Infect (2008) 10:1567-76. doi:10.1016/j.micinf.2008.09.011
183. Thomas A, Gasque P, Vaudry D, Gonzalez B, Fontaine M. Expression of a complete and functional complement system by human neuronal cells in vitro. Int Immunol (2000) 12:1015-23. doi:10.1093/intimm/12.7.1015
184. Fan R, Tenner AJ. Complement C1q expression induced by Abeta in rat hippocampal organotypic slice cultures. Exp Neurol (2004) 185:241-53. doi:10.1016/j.expneurol.2003.09.023
185. Benoit ME, Tenner AJ. Complement protein C1q-mediated neuroprotection is correlated with regulation of neuronal gene and microRNA expression. J Neurosci (2011) 31:3459-69. doi:10.1523/JNEUROSCI.3932-10.2011
186. Budka H. Neuropathology of prion diseases. Br Med Bull (2003) 66:121-30. doi:10.1093/bmb/66.1.121
187. Hilton KJ, Cunningham C, Reynolds RA, Perry VH. Early hippocampal synaptic loss precedes neuronal loss and associates with early behavioural deficits in three distinct strains of prion disease. PLoS One (2013) 8:e68062. doi:10.1371/journal.pone.0068062
188. Mitchell DA. Transmissible spongiform encephalopathies-passage from gut to brain. In: Kishore U, Nayak A, editors. Microbial Pathogenesis: Infection and Immunity. New York: Landes Bioscience and Springer Science+Business Media (2013). p. 276-85.
189. Michel B, Meyerett-Reid C, Johnson T, Ferguson A, Wyckoff C, Pulford B, et al. Incunabular immunological events in prion trafficking. Sci Rep (2012) 2:440. doi:10.1038/srep00440
190. Mitchell DA, Kirby L, Paulin SM, Villiers CL, Sim RB. Prion protein activates and fixes complement directly via the classical pathway: implications for the mechanism of scrapie agent propagation in lymphoid tissue. Mol Immunol (2007) 44:2997-3004. doi:10.1016/j.molimm.2006.12.027
191. Mabbott NA, Mackay F, Minns F, Bruce ME. Temporary inactivation of follicular dendritic cells delays neuroinvasion of scrapie. Nat Med (2000) 6:719-20. doi:10.1038/77401
192. Veerhuis R, Boshuizen RS, Morbin M, Mazzoleni G, Hoozemans JJ, Langedijk JP, et al. Activation of human microglia by fibrillar prion protein-related peptides is enhanced by amyloid-associated factors SAP and C1q. Neurobiol Dis (2005) 19:273-82. doi:10.1016/j.nbd.2005.01.005
193. Bialas AR, Stevens B. TGF-beta signaling regulates neuronal C1q expression and developmental synaptic refinement. Nat Neurosci (2013) 16:1773-82. doi:10.1038/nn.3560
194. Chu Y, Jin X, Parada I, Pesic A, Stevens B, Barres B, et al. Enhanced synaptic connectivity and epilepsy in C1q knockout mice. Proc Natl Acad Sci U S A (2010) 107:7975-80. doi:10.1073/pnas.0913449107
195. Ma Y, Ramachandran A, Ford N, Parada I, Prince DA. Remodeling of dendrites and spines in the C1q knockout model of genetic epilepsy. Epilepsia (2013) 54:1232-9. doi:10.1111/epi.12195
196. Aronica E, Boer K, van Vliet EA, Redeker S, Baayen JC, Spliet WG, et al. Complement activation in experimental and human temporal lobe epilepsy. Neurobiol Dis (2007) 26:497-511. doi:10.1016/j.nbd.2007.01.015
197. Stephan AH, Madison DV, Mateos JM, Fraser DA, Lovelett EA, Coutellier L, et al. A dramatic increase of C1q protein in the CNS during normal aging. J Neurosci (2013) 33:13460-74. doi:10.1523/JNEUROSCI.1333-13.2013
198. Mallucci GR. Prion neurodegeneration: starts and stops at the synapse. Prion (2009) 3:195-201. doi:10.4161/pri.3.4.9981
199. Selkoe DJ. Alzheimer's disease is a synaptic failure. Science (2002) 298:789-91. doi:10.1126/science.1074069
200. Dvorak HF, Brown LF, Detmar M, Dvorak AM. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol (1995) 146(5):1029-39.
201. Chung AS, Ferrara N. Developmental and pathological angiogenesis. Annu Rev Cell Dev Biol (2011) 27:563-84. doi:10.1146/annurev-cellbio-092910-154002